Antibody–drug conjugates as novel anti-cancer chemotherapeutics

布仑妥昔单抗维多汀 单克隆抗体 抗体-药物偶联物 抗原 药理学 癌症 药品 癌症研究 癌细胞 抗体 连接器 医学 化学 免疫学 内科学 计算机科学 肿瘤细胞 操作系统 CD30
作者
Christina Peters,Stuart Brown
出处
期刊:Bioscience Reports [Portland Press]
卷期号:35 (4) 被引量:474
标识
DOI:10.1042/bsr20150089
摘要

Over the past couple of decades, antibody-drug conjugates (ADCs) have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize monoclonal antibodies (mAbs) to specifically bind tumour-associated target antigens and deliver a highly potent cytotoxic agent. The synergistic combination of mAbs conjugated to small-molecule chemotherapeutics, via a stable linker, has given rise to an extremely efficacious class of anti-cancer drugs with an already large and rapidly growing clinical pipeline. The primary objective of this paper is to review current knowledge and latest developments in the field of ADCs. Upon intravenous administration, ADCs bind to their target antigens and are internalized through receptor-mediated endocytosis. This facilitates the subsequent release of the cytotoxin, which eventually leads to apoptotic cell death of the cancer cell. The three components of ADCs (mAb, linker and cytotoxin) affect the efficacy and toxicity of the conjugate. Optimizing each one, while enhancing the functionality of the ADC as a whole, has been one of the major considerations of ADC design and development. In addition to these, the choice of clinically relevant targets and the position and number of linkages have also been the key determinants of ADC efficacy. The only marketed ADCs, brentuximab vedotin and trastuzumab emtansine (T-DM1), have demonstrated their use against both haematological and solid malignancies respectively. The success of future ADCs relies on improving target selection, increasing cytotoxin potency, developing innovative linkers and overcoming drug resistance. As more research is conducted to tackle these issues, ADCs are likely to become part of the future of targeted cancer therapeutics.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
芽芽发布了新的文献求助10
1秒前
2秒前
李博宇发布了新的文献求助10
3秒前
lele发布了新的文献求助10
3秒前
Ava的应助被1900采纳,获得30
3秒前
拉长的冰淇淋完成签到 ,获得积分10
3秒前
茉莉媛完成签到 ,获得积分10
3秒前
甜甜胡萝卜完成签到 ,获得积分10
5秒前
今后的应助被三分之二采纳,获得10
5秒前
6秒前
null的应助被科研通管家采纳,获得10
6秒前
大个的应助被科研通管家采纳,获得10
6秒前
斯文败类的应助被科研通管家采纳,获得10
6秒前
英姑的应助被科研通管家采纳,获得10
6秒前
充电宝的应助被科研通管家采纳,获得10
6秒前
梨花香发布了新的文献求助10
6秒前
CodeCraft的应助被科研通管家采纳,获得10
7秒前
7秒前
微风无起发布了新的文献求助10
7秒前
思源的应助被科研通管家采纳,获得30
7秒前
爆米花的应助被科研通管家采纳,获得10
7秒前
共享精神的应助被科研通管家采纳,获得10
7秒前
kkscanl完成签到 ,获得积分10
7秒前
大模型的应助被科研通管家采纳,获得10
7秒前
酷波er的应助被科研通管家采纳,获得10
7秒前
慕青的应助被科研通管家采纳,获得10
7秒前
彭于晏的应助被科研通管家采纳,获得10
7秒前
null的应助被科研通管家采纳,获得10
8秒前
赘婿的应助被科研通管家采纳,获得10
8秒前
8秒前
红果完成签到,获得积分10
8秒前
思源的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
搜集达人的应助被xm采纳,获得10
8秒前
大个的应助被科研通管家采纳,获得10
8秒前
8秒前
unik完成签到,获得积分20
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177802
求助须知:如何正确求助?哪些是违规求助? 9568632
关于积分的说明 21799933
捐赠科研通 7772424
什么是DOI,文献DOI怎么找? 3432505
关于科研通互助平台的介绍 2556698
邀请新用户注册赠送积分活动 2478055